Author

Shahram Jacobs

Observed name: Jacobs, Shahram

Institutions: University of California, Los Angeles, Arlington Dermatology, Probity Medical Research, Alumis Inc. (United States)

Observed institutions: University of California, Los Angeles, Arlington Dermatology, Probity Medical Research, Alumis Inc. (United States)

OpenAlex ID: A5113977263

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

2018 · Adrian F Hernandez, Jennifer B Green, et al. · The Lancet · 1,822

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

2019 · A. Blauvelt, A. Blauvelt, et al. · British Journal of Dermatology · 175

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study

2025 · Kim A. Papp, Shahram Jacobs, et al. · Journal of the American Academy of Dermatology · 7

Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial

2025 · Joanna Narbutt, Shahram Jacobs, et al. · SKIN The Journal of Cutaneous Medicine

Works count: 5

Citation count: 2,004

H-index: 3

I10-index: 2